Affinia Therapeutics
4 known investors
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions. The company uses AI and structural modeling to redesign viral delivery vectors for one-time-dose genetic medicines across rare and prevalent diseases.
AI & Machine LearningBiotechDeep Tech
Investors · 4
In the news
- Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathyclinicaltrialsarena.com · 2026
- Affinia raises $40m for gene therapy developmentyahoo.com · 2025
- Affinia Therapeutics Raises $40M in Series C Financingfinsmes.com · 2025
- Affinia Therapeutics' $40M Funding: A Catalyst for Biotech Breakthroughs?ainvest.com · 2025
- Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacybusinesswire.com · 2025
- Affinia Therapeutics raises $110 million for gene therapy treatmentsstatnews.com · 2021